The treatment of osteosarcoma, is threat and the most common tumor of bone, but a new study is offering hope to patients with this disease.
Over the last 25 years, the five-year survival rate has remained unchanged for bone cancer, and the treatment options for these patients are few.
Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs.
A study led by a popular university of Texas found a drug known as bone metastasis-targeting peptidomimetic (BMTP-11) has potential as a new therapeutic strategy for this devastating illness.
Giving blood and platelets provides hope for cancer patients who depend on the generosity of donors.
Picture courtesy: – https://encrypted-tbn0.gstatic.com/images